Global metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant Acinetobacter baumannii

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Maifiah, Mohd Hafidz Mahamad ^a   Cheah, Soon Ee ^a   Johnson, Matthew D ^a   Han, Mei Ling ^a   Boyce, John D ^a   Thamlikitkul, Visanu ^b   Forrest, Alan ^c   Kaye, Keith S ^d   Hertzog, Paul ^a,e   Purcell, Anthony W ^a   Song, Jiangning ^a   Velkov, Tony ^a   Creek, Darren J ^a   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; LIPID A; POLYMYXIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; CHEMISTRY; CLUSTER ANALYSIS; DRUG EFFECTS; ENERGY METABOLISM; GENETICS; GENOMICS; MASS SPECTROMETRY; METABOLISM; METABOLOME; METABOLOMICS; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PROCEDURES;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; CLUSTER ANALYSIS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENERGY METABOLISM; GENOMICS; LIPID A; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; MICROBIAL SENSITIVITY TESTS; POLYMYXINS;

EID: 84959319307     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22287     Document Type: Article

References (69)

1. Peleg, A. Y., Seifert, H. & Paterson, D. L. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21, 538-582 (2008).
2. Dijkshoorn, L., Nemec, A. & Seifert, H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat. Rev. Microbiol. 5, 939-951 (2007).
3. Maragakis, L. L. & Perl, T. M. Acinetobacter baumannii: Epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 46, 1254-1263 (2008).
4. Boucher, H. W. et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1-12 (2009).
5. Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2013. (2013). Available at: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. (Accessed: 17th February 2016).
6. Perez, F. et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51, 3471-3484 (2007).
7. Velkov, T., Roberts, K. D., Nation, R. L., Thompson, P. E. & Li, J. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics. Future Microbiol. 8, 711-724 (2013).
8. Li, J. et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6, 589-601 (2006).
9. Gordon, N. C. & Wareham, D. W. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int. J. Antimicrob. Agents. 35, 219-226 (2010).
10. Arnold, T. M., Forrest, G. N. & Messmer, K. J. Polymyxin antibiotics for Gram-negative infections. Am. J. Health Syst. Pharm. 64, 819-826 (2007).
11. Karageorgopoulos, D. E. & Falagas, M. E. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect. Dis. 8, 751-762 (2008).
12. Hancock, R. E. W. Peptide antibiotics. Lancet 349, 418-422 (1997).
13. Sampson, T. R. et al. Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway. Antimicrob. Agents Chemother. 56, 5642-5649 (2012).
14. Beceiro, A. et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob. Agents Chemother. 55, 3370-3379 (2011).
15. Arroyo, L. A. et al. The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. Antimicrob. Agents Chemother. 55, 3743-3751 (2011).
16. Pelletier, M. R. et al. Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii. Antimicrob. Agents Chemother. 57, 4831-4840 (2013).
17. Moffatt, J. H. et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob. Agents Chemother. 54, 4971-4977 (2010).
18. Henry, R. et al. Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-β-1,6-Nacetylglucosamine. Antimicrob. Agents Chemother. 56, 59-69 (2012).
19. Van der Werf, M. J., Overkamp, K. M., Muilwijk, B., Coulier, L. & Hankemeier, T. Microbial metabolomics: toward a platform with full metabolome coverage. Anal. Biochem. 370, 17-25 (2007).
20. Snyder, M. & Li, X. Y. Metabolomics as a robust tool in systems biology and personalized medicine: an open letter to the metabolomics community. Metabolomics 9, 532-534 (2013).
21. Putri, S. P. et al. Current metabolomics: practical applications. J. Biosci. Bioeng. 115, 579-589 (2013).
22. Beyoglu, D. & Idle, J. R. Metabolomics and its potential in drug development. Biochem. Pharmacol. 85, 12-20 (2013).
23. Kell, D. B. & Goodacre, R. Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery. Drug Discov. Today 19, 1828-1828 (2014).
24. Tang, J. Microbial metabolomics. Curr. Genomics 12, 391-403 (2011).
25. Yeom, J., Shin, J. H., Yang, J. Y., Kim, J. & Hwang, G. S. H-1 NMR-based metabolite profiling of planktonic and biofilm cells in Acinetobacter baumannii 1656-2. Plos One 8, e57730 (2013).
26. Gjersing, E. L., Herberg, J. L., Horn, J., Schaldach, C. M. & Maxwell, R. S. NMR metabolomics of planktonic and biofilm modes of growth in Pseudomonas aeruginosa. Anal. Chem. 79, 8037-8045 (2007).
27. t'Kindt, R. et al. Metabolomics to unveil and understand phenotypic diversity between pathogen populations. Plos Negl. Trop. Dis. 4, e904 (2010).
28. Vincent, I. M. et al. A molecular mechanism for eflornithine resistance in African trypanosomes. PLoS Pathog. 6, e1001204 (2010).
29. Derewacz, D. K., Goodwin, C. R., McNees, C. R., McLean, J. A. & Bachmann, B. O. Antimicrobial drug resistance affects broad changes in metabolomic phenotype in addition to secondary metabolism. Proc. Natl. Acad. Sci. USA 110, 2336-2341 (2013).
30. Iacono, M. et al. Whole-genome pyrosequencing of an epidemic multidrug-resistant Acinetobacter baumannii strain belonging to the European clone II group. Antimicrob. Agents Chemother. 52, 2616-2625 (2008).
31. Raetz, C. R., Reynolds, C. M., Trent, M. S. & Bishop, R. E. Lipid A modification systems in Gram-negative bacteria. Annu. Rev. Biochem. 76, 295-329 (2007).
32. Nowicki, E. M., O'Brien, J. P., Brodbelt, J. S. & Trent, M. S. Characterization of Pseudomonas aeruginosa LpxT reveals dual positional lipid A kinase activity and co-ordinated control of outer membrane modification. Mol. Microbiol. 94, 728-741 (2014).
33. Velkov, T., Thompson, P. E., Nation, R. L. & Li, J. Structure-activity relationships of polymyxin antibiotics. J. Med. Chem. 53, 1898-1916 (2009).
34. Yu, Z., Qin, W., Lin, J., Fang, S. & Qiu, J. Antibacterial mechanisms of polymyxin and bacterial resistance. BioMed Res. Int. 2015, 1-11 (2015).
35. Meyer, H., Weidmann, H. & Lalk, M. Methodological approaches to help unravel the intracellular metabolome of Bacillus subtilis. Microb. Cell Fact. 12, 69 (2013).
36. Marcinowska, R., Trygg, J., Wolf-Watz, H., Mortiz, T. & Surowiec, I. Optimization of a sample preparation method for the metabolomic analysis of clinically relevant bacteria. J. Microbiol. Methods 87, 24-31 (2011).
37. Rabinowitz, J. D. Cellular metabolomics of Escherchia coli. Expert Rev Proteomic 4, 187-198 (2007).
38. Wittmann, C., Kromer, J. O., Kiefer, P., Binz, T. & Heinzle, E. Impact of the cold shock phenomenon on quantification of intracellular metabolites in bacteria. Anal. Biochem. 327, 135-139 (2004).
39. Shin, M. H., Lee, D. Y., Liu, K. H., Fiehn, O. & Kim, K. H. Evaluation of sampling and extraction methodologies for the global metabolic profiling of Saccharophagus degradans. Anal. Chem. 82, 6660-6666 (2010).
40. Armenta-Medina, D., Segovia, L. & Perez-Rueda, E. Comparative genomics of nucleotide metabolism: a tour to the past of the three cellular domains of life. BMC Genomics 15 (2014).
41. Maeda, H. & Dudareva, N. The shikimate pathway and aromatic amino acid biosynthesis in plants. Annu. Rev. Plant Biol. 63, 73-105 (2012).
42. Stincone, A. et al. The return of metabolism: biochemistry and physiology of the pentose phosphate pathway. Biol. Rev. 90, 927-963 (2015).
43. Taylor, P. L. et al. Structure and function of sedoheptulose-7-phosphate isomerase, a critical enzyme for lipopolysaccharide biosynthesis and a target for antibiotic adjuvants. J. Biol. Chem. 283, 2835-2845 (2008).
44. Sarkar, M., Maganti, L., Ghoshal, N. & Dutta, C. In silico quest for putative drug targets in Helicobacter pylori HPAG1: molecular modeling of candidate enzymes from lipopolysaccharide biosynthesis pathway. J. Mol. Model. 18, 1855-1866 (2012).
45. Kneidinger, B., Graninger, M., Puchberger, M., Kosma, P. & Messner, P. Biosynthesis of nucleotide-activated D-glycero-D-manno-Heptose. J. Biol. Chem. 276, 20935-20944 (2001).
46. Valvano, M. A., Messner, P. & Kosma, P. Novel pathways for biosynthesis of nucleotide-activated glycero-manno-heptose precursors of bacterial glycoproteins and cell surface polysaccharides. Microbiol. SGM. 148, 1979-1989 (2002).
47. Tian, J., Bryk, R., Itoh, M., Suematsu, M. & Nathan, C. Variant tricarboxylic acid cycle in Mycobacterium tuberculosis: Identification of α-ketoglutarate decarboxylase. Proc. Natl. Acad. Sci. USA 102, 10670-10675 (2005).
48. Lovering, A. L., Safadi, S. S. & Strynadka, N. C. Structural perspective of peptidoglycan biosynthesis and assembly. Annu. Rev. Biochem. 81, 451-478 (2012).
49. Gordon, E. et al. Crystal structure of UDP-N-acetylmuramoyl-L-alanyl-D-glutamate: meso-diaminopimelate ligase from Escherichia coli. J. Biol. Chem. 276, 10999-11006 (2001).
50. Rudulier, D. L. Elucidation of the role of osmoprotective compounds and osmoregulatory genes: The key role of bacteria. (eds. Lieth, H. & Al Masoom, A.) Towards the rational use of high salinity tolerant plants. I, 313-322 (Kluwer Academic Publishers, 1993).
51. Dalebroux, Z. D., Matamouros, S., Whittington, D., Bishop, R. E. & Miller, S. I. PhoPQ regulates acidic glycerophospholipid content of the Salmonella Typhimurium outer membrane. Proc. Natl. Acad. Sci. USA 111, 1963-1968 (2014).
52. Geiger, O., Lopez-Lara, I. M. & Sohlenkamp, C. Phosphatidylcholine biosynthesis and function in bacteria. BBA-Mol. Cell Biol. L. 1831, 503-513 (2013).
53. Steeghs, L. et al. Outer membrane composition of a lipopolysaccharide-deficient Neisseria meningitidis mutant. EMBO J. 20, 6937-6945 (2001).
54. Garsin, D. A. Ethanolamine utilization in bacterial pathogens: roles and regulation. Nature Rev. Microbiol. 8, 290-295 (2010).
55. Kendall, M. M., Gruber, C. C., Parker, C. T. & Sperandio, V. Ethanolamine controls expression of genes encoding components involved in interkingdom signaling and virulence in enterohemorrhagic Escherichia coli O157:H7. mBio. 3, e00050-12 (2012).
56. Bowen, B. P. & Northen, T. R. Dealing with the unknown: metabolomics and metabolite atlases. J. Am. Soc. Mass Spectr. 21, 1471-1476 (2010).
57. Nakabayashi, R. & Saito, K. Metabolomics for unknown plant metabolites. Anal. Bioanal. Chem. 405, 5005-5011 (2013).
58. Gowda, G. A. N. & Raftery, D. Can NMR solve some significant challenges in metabolomics? J. Magn. Reson. 260, 144-160 (2015).
59. Garonzik, S. M. et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55, 3284-3294 (2011).
60. Que, N. L., Lin, S., Cotter, R. J. & Raetz, C. R. Purification and mass spectrometry of six lipid A species from the bacterial endosymbiont Rhizobium etli. Demonstration of a conserved distal unit and a variable proximal portion. J. Biol. Chem. 275, 28006-28016 (2000).
61. Bligh, E. G. & Dyer, W. J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911-917 (1959).
62. Gika, H. G., Theodoridis, G. A., Wingate, J. E. & Wilson, I. D. Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. J. Proteome Res. 6, 3291-3303 (2007).
63. Zhang, T., Creek, D. J., Barrett, M. P., Blackburn, G. & Watson, D. G. Evaluation of coupling reversed phase, aqueous n\ormal phase, and hydrophilic interaction liquid chromatography with orbitrap mass spectrometry for metabolomic studies of human urine. Anal. Chem. 84, 1994-2001 (2012).
64. Scheltema, R. A., Jankevics, A., Jansen, R. C., Swertz, M. A. & Breitling, R. PeakML/mzMatch: a file format, Java library, R library, and tool-chain for mass spectrometry data analysis. Anal. Chem. 83, 2786-2793 (2011).
65. Creek, D. J., Jankevics, A., Burgess, K. E., Breitling, R. & Barrett, M. P. IDEOM: an Excel interface for analysis of LC-MS-based metabolomics data. Bioinformatics 28, 1048-1049 (2012).
66. Smith, C. A., Want, E. J., O'Maille, G., Abagyan, R. & Siuzdak, G. XCMS: Processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 78, 779-787 (2006).
67. Leader, D. P., Burgess, K., Creek, D. & Barrett, M. P. Pathos: A web facility that uses metabolic maps to display experimental changes in metabolites identified by mass spectrometry. Rapid Commun. Mass Spectrom. 25, 3422-3426 (2011).
68. Caspi, R. et al. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of Pathway/Genome Databases. Nucleic Acids Res. 42, 459-471 (2014).
69. Junker, B. H., Klukas, C. & Schreiber, F. VANTED: a system for advanced data analysis and visualization in the context of biological networks. BMC bioinform. 7, 109 (2006).